Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and DDI Study of Tasfygo (E7090) in Healthy Subjects
NCT04565574Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tasurgratinib in cholangiocarcinoma (CCA) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-time Curve From Zero to Last Quantifiable Concentration and 1 more. Started Oct 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04565574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565574.